irinotecan/deltapharma c/s.sol.in 20mg/ml
deltapharma limited, u.k. regent house, 316 beulah hill,, london se19 3hf, - irinotecan hydrochloride trihydrate - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 20mg/ml - irinotecan hydrochloride trihydrate 20mg - irinotecan
irinotecan/medicus c/s.sol.in 20mg/1ml
medicus a.e. Βαλαωρίτου 10,, 144 52 144 52, Μεταμόρφωση Αττικής 28 15 353, 28 43 479 - irinotecan hydrochloride trihydrate - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 20mg/1ml - irinotecan hydrochloride trihydrate 20mg - irinotecan
irinotecan/thama c/s.sol.in 20mg/ml
thama a.e. Ρούμελης 42,, 152 33 152 33, Χαλάνδρι 210.6828622 - irinotecan hydrochloride trihydrate - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 20mg/ml - irinotecan hydrochloride trihydrate 20mg - irinotecan
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - Καρκίνωμα, σκουός κύτταρο - Αντινεοπλασματικοί παράγοντες - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
gallimune se + st, ενέσιμο γαλάκτωμα (νερό σε λάδι)
qi01ab01 - granted - boehringer ingelheim animal health france scs - vaccine - activet ltd
amodiaquine 200mg tablets
remedica ltd (0000003171) aharnon str., lemesos, 3056 - amodiaquine hydrochloride - tablets - 200mg - amodiaquine hydrochloride (0006398987) 200mg base - amodiaquine
piperacillin+tazobactam/generics pd.sol.inf (2+0,25)g/vial
generics pharma hellas ΕΠΕ Αγίου Δημητρίου 63, 17456 Αλιμος 210.9936410 - piperacillin sodium; tazobactam sodium - pd.sol.inf (ΚΟΝΙΣ ΓΙΑ ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - (2+0,25)g/vial - piperacillin sodium 2,085g; tazobactam sodium 263,3mg - piperacillin and enzyme inhibitor
piperacillin+tazobactam/generics pd.sol.inf (4+0,5)g/vial
generics pharma hellas ΕΠΕ Αγίου Δημητρίου 63, 17456 Αλιμος 210.9936410 - piperacillin sodium; tazobactam sodium - pd.sol.inf (ΚΟΝΙΣ ΓΙΑ ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - (4+0,5)g/vial - piperacillin sodium 4,17g; tazobactam sodium 536,6mg - piperacillin and enzyme inhibitor
piperacillin+tazobactam/kabi pd.sol.inf 2g/0,250g
fresenius kabi hellas ae Λεωφ. Κηφισίας 64Α, 151 25 Μαρούσι Αττικής 6542909 - piperacillin sodium; tazobactam sodium - pd.sol.inf (ΚΟΝΙΣ ΓΙΑ ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 2g/0,250g - piperacillin sodium 2,085g; tazobactam sodium 268,3mg - piperacillin and enzyme inhibitor
piperacillin+tazobactam/kabi pd.sol.inf 4g/0,500g
fresenius kabi hellas ae Λεωφ. Κηφισίας 64Α, 151 25 Μαρούσι Αττικής 6542909 - piperacillin sodium; tazobactam sodium - pd.sol.inf (ΚΟΝΙΣ ΓΙΑ ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 4g/0,500g - piperacillin sodium 4,17g; tazobactam sodium 536,6mg - piperacillin and enzyme inhibitor